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grin is a motor neuron–derived factor that directs
formation of the postsynaptic apparatus of the neuro-
muscular junction. Agrin is also expressed in the
brain, raising the possibility that it might serve a related
function at neuron–neuron synapses. Previously, we identi-
ﬁed an agrin signaling pathway in central nervous system
(CNS) neurons, establishing the existence of a neural receptor
that mediates responses to agrin. As a step toward identifying
this agrin receptor, we have characterized the minimal
domains in agrin that bind and activate it. Structures required
for agrin signaling in CNS neurons are contained within a
A
 
20-kD COOH-terminal fragment of the protein. Agrin signal-
ing is independent of alternative splicing at the z site, but
requires sequences that ﬂank it because their deletion results
in a 15-kD fragment that acts as an agrin antagonist. Thus,
distinct regions within agrin are responsible for receptor
binding and activation. Using the minimal agrin fragments
as afﬁnity probes, we also studied the expression of the
agrin receptor on CNS neurons. Our results show that both
agrin and its receptor are concentrated at neuron–neuron
synapses. These data support the hypothesis that agrin
plays a role in formation and/or function of CNS synapses.
 
Introduction
 
The hypothesis that agrin mediates the motor neuron–induced
accumulation of acetylcholine receptors (AChRs)* at the
neuromuscular junction is now widely accepted (for review
see Hoch, 1999). Although a complete account of how agrin
triggers such changes in AChR distribution has yet to be
established, much of what we know about this process has
been learned from structural studies of agrin and the proteins
with which it interacts.
Native agrin is an 
 
 
 
400-kD heparan sulfate proteoglycan
 
assembled on an 
 
 
 
200-kD polypeptide backbone characterized
by multiple cysteine-rich domains homologous to other
ECMs and secreted proteins (Fig. 1). Structural determinants
required for agrin’s AChR clustering activity are localized to
its 95-kD COOH-terminal half distinguished by the presence
of four EGF repeats and three laminin-like G domains
(Ferns et al., 1993). Relatively little is known about the
properties of the EGF repeats, but functions of the G domains
are better understood. For example, 
 
 
 
-dystroglycan, a com-
ponent of the dystrophin-associated glycoprotein complex
expressed on the surface membranes of skeletal muscle fibers,
binds to a region within the G1/G2 domain (Gesemann et
al., 1996; Hopf and Hoch, 1996). However, neither the G1
nor G2 domains are required for agrin’s AChR clustering
activity, which instead is a property of a 21-kD COOH-
terminal region consisting of the G3 domain and the alter-
natively spliced z site (Gesemann et al., 1995, 1996). The
receptor that mediates agrin-induced clustering of AChRs in
muscle is a complex consisting of a muscle-specific kinase
(MuSK) and an as yet to be identified myotube-associated
specificity component (MASC; Glass et al., 1996). Thus,
structural elements sufficient to bind and activate the
MuSK–MASC receptor are present within 21 kD of agrin’s
COOH terminus. However, the observation that the AChR
clustering activity of the 21-kD fragment is markedly lower
than the 95-kD fragment (Gesemann et al., 1995) suggests
the G1/G2 domains and/or EGF repeats also contribute to
agrin’s activity, either by stabilizing the structure of the active
site or binding to a component on the muscle cell surface.
Many populations of neurons in brain also express agrin,
and several lines of evidence support a role for agrin in neuronal
synaptogenesis analogous to that at the neuromuscular junc-
tion.  Agrin is concentrated at neuron–neuron synapses
(Mann and Kröger, 1996; Koulen et al., 1999; Gingras and
Ferns, 2001), and suppressing agrin expression in cultured
hippocampal neurons with antisense oligonucleotides inhibits
 
accumulation of neurotransmitter receptors and other postsyn-
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aptic markers at synaptic sites (Ferreira, 1999; Böse et al.,
2000). However, other papers have suggested alternate or
additional neural functions for agrin. Consistent with a role
as a “stop and differentiation” signal (Campagna et al.,
1995), blocking agrin expression in cultured hippocampal
neurons alters rates of axonal and dendritic elongation
(Mantych and Ferreira, 2001) and inhibits differentiation of
presynaptic terminals (Böse et al., 2000). In fact, the recent
finding that agrin-deficient neurons exhibit altered responses
to transient changes in cytoplasmic Ca
 
2
 
 
 
 suggests the poten-
tial to modulate a wide range of processes in brain (Hilgen-
berg et al., 2002).
Little is known about the receptor(s) that might mediate
agrin’s effects in neurons. However, using the immediate early
gene 
 
c-fos
 
 as a reporter, we have identified an agrin-dependent
signaling pathway in central nervous system (CNS) neurons,
providing evidence that a neuronal receptor for agrin does ex-
ist (Hilgenberg et al., 1999). Agrin signaling in neurons shares
several biochemical similarities with that in muscle, includ-
ing concentration dependence, requirement for extracellular
Ca
 
2
 
 
 
, and inhibition by heparin. However, unlike AChR
clustering, which is exquisitely sensitive to splicing at the z site
(Ferns et al., 1992; Ruegg et al., 1992; Gesemann et al.,
1995), agrin z
 
 
 
 and z
 
 
 
 isoforms are equally potent activators
of the agrin signal pathway in neurons (Hilgenberg et al.,
1999). To learn more about the nature of the neuronal recep-
tor for agrin, we analyzed the functional properties of deletion
mutants derived from the 95-kD COOH-terminal fragment
used in our original works. Our results provide evidence for a
novel neuronal receptor for agrin concentrated at synapses
formed between CNS neurons.
 
Results
 
Agrin signaling in neurons is independent of 
splicing at the z site
 
Our initial characterization of the agrin signal transduction
pathway in CNS neurons demonstrated its inability to dis-
criminate between “active” z
 
 
 
 and “inactive” z
 
 
 
 agrin iso-
forms (Hilgenberg et al., 1999). However, these works used
alternatively spliced variants of the 95-kD COOH-terminal
region of rat agrin (rC-Ag
 
z0/8
 
), and were limited by the fact
that only indirect estimates of agrin concentration could be
made, leaving open the possibility that some difference in
the specific activities of alternatively spliced isoforms might
have gone undetected. To address this issue directly, new
95-kD mouse agrin constructs (Fig. 1; C-Ag95
 
z0/8
 
) were as-
sembled in the pSecTag2 expression vector (Invitrogen), in-
corporating COOH-terminal myc and polyhistidine epitope
tags, permitting purification and detection of the expressed
protein and accurate concentration measurement to be made
(see Materials and methods). Because the vast majority of
agrin molecules expressed in brain include the 4 amino acid
exon at the y site (Hoch et al., 1993; Li et al., 1997), all
Figure 1. The structure of agrin and agrin deletion constructs used in this paper. Alternate transcriptional start sites give rise to short and 
long NH2-terminal (SN, LN) forms of agrin. Agrin’s polypeptide chain is characterized by numerous cysteine-rich repeats similar to follistatin 
(F), laminin B (LB), EGF (E), and laminin A G domains (G). Two serine/threonine-rich regions (S/T), consensus glycosaminoglycans side-chain 
attachment sites (lollipops), and sites of alternative splicing (X, Y, Z) are also shown. Horizontal bars indicate location of binding sites for 
various cell surface and ECM molecules. The minimal region required for agrin’s AChR clustering activity is also shown. Agrin deletion 
constructs C-Ag95z0/8 and C-Ag 20 included an NH2-terminal signal peptide for expression in mammalian cells and 4 amino acid insert at 
the y site. All deletion constructs included COOH-terminal myc (m) and polyhistidine (H) epitope tags.T
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agrin constructs included the y4 exon, and only the proper-
ties of z-site variants were examined.
Rat rC-Ag
 
z0
 
 and rC-Ag
 
z8
 
 induce a neuron-specific increase
in Fos expression (Hilgenberg et al., 1999). To confirm the
properties of the corresponding mouse constructs, 12-d-old
cortical cultures were treated with 1 nM purified mouse
C-Ag95
 
z0
 
 or C-Ag95
 
z8
 
, and were then double labeled with
antibodies against Fos and either microtubule-associated
protein 2 (MAP2) or glial fibrillary acidic protein (GFAP) to
identify neurons and glial cells, respectively. Consistent with
our previous results, treatment with either C-Ag95
 
z0
 
 or
C-Ag95
 
z8
 
 caused a marked increase in Fos expression in neu-
rons, but not nonneuronal cells (Fig. 2). Although differ-
ences in the level of Fos expression between neurons were
apparent, virtually all neurons (
 
 
 
90%) responded to the
C-Ag95
 
z0/8
 
 treatment. In contrast, treatment with a similar
concentration of prostate serum antigen control protein ex-
pressed in the same vector had no effect on Fos levels in ei-
ther neurons or glia (Fig. 2). In light of these results, we con-
clude that neither the myc epitope nor polyhistidine tags
induce 
 
c-fos
 
, nor do they affect the ability of the C-Ag95
 
z0/8
 
sequences to do so.
Next, we determined the specific activity of each z-site iso-
form using an in situ enzyme-linked immunoassay (Hilgen-
berg et al., 1999) to examine the concentration dependence
of 
 
c-fos
 
 induction by C-Ag95
 
z0
 
 and C-Ag95
 
z8
 
. As shown in
Fig. 2 B, both agrin isoforms induced 
 
c-fos
 
 in a concentra-
tion-dependent and saturable fashion. Fos expression curves
were well fit by a single-site nonlinear regression model
(R
 
2
 
 
 
 
 
 0.94) predicting EC
 
50
 
 values of 11.93 
 
 
 
 0.44 pM for
C-Ag95
 
z0
 
 and 12.67 
 
 
 
 0.58 pM for C-Ag95
 
z8
 
 (mean 
 
 
 
SEM). Similar EC
 
50
 
 values have also been reported for agrin-
induced clustering of AChR in muscle, but in contrast to the
 
 
 
1,000-fold difference in AChR clustering activity between
isoforms (Ferns et al., 1992; Ruegg et al., 1992; Gesemann
et al., 1995), the 
 
c-fos
 
–inducing activity of C-Ag95
 
z8
 
 and
C-Ag95
 
z0
 
 in neurons is the same.
 
The 20-kD COOH-terminal portion of agrin is 
necessary and sufficient for signaling in neurons
 
As a first step in localizing the structural domains responsible
for signaling in neurons, we took advantage of knowledge
gained from previous structural analyses of agrin function in
muscle (Hoch et al., 1994; Gesemann et al., 1995, 1996) and
divided C-Ag95
 
z0/8
 
 into two fragments. The first, an 75-kD
NH
 
2
 
-terminal fragment (Fig. 1; C-Ag
 
 
 
20), which includes
the 4 amino acid exon at the y site, has been shown to mediate
agrin binding to 
 
 
 
-dystroglycan (Gesemann et al., 1996; Hopf
and Hoch, 1996). The remaining 20-kD COOH-terminal
fragment contains the alternatively spliced z site (Fig. 1;
C-Ag20
 
z0
 
 or C-Ag20
 
z8
 
), and is homologous to the minimal
agrin fragment able to induce clustering of AChR in cultured
muscle cells (Gesemann et al., 1995).
Treatment with C-Ag
 
 
 
20, at a concentration equivalent
to either a near saturating (50 pM) or supersaturating (5
nM) amount of C-Ag95
 
z0/8
 
, had no effect on Fos expression
in cortical cultures, suggesting that the active domain is not
present within the C-Ag
 
 
 
20 region (Fig. 3 A). Agrin bind-
ing to 
 
 
 
-dystroglycan has been shown to modulate agrin-
induced AChR clustering in muscle, and we considered the
 
possibility of a similar function for 
 
 
 
-dystroglycan signaling
in neurons. However, coincubation with either an equal or
100-fold molar excess of C-Ag
 
 
 
20 had no effect on Fos ex-
pression induced by either the C-Ag95
 
z0
 
 or C-Ag95
 
z8
 
 iso-
forms (Fig. 3 A). Together, these data suggest that domains
present within C-Ag
 
 
 
20 are neither required for, nor modu-
late, agrin induction of 
 
c-fos
 
 in neurons.
The C-Ag20 fragments were both potent inducers of
 
c-fos
 
. As with C-Ag95
 
z0/8
 
, 
 
c-fos
 
 induction by C-Ag20
 
z0
 
 and
C-Ag20
 
z8
 
 was concentration-dependent and saturable (Fig. 3
B). In fact, the EC
 
50
 
 values obtained for the 20-kD fragments
(C-Ag20
 
z0
 
, 13.33 
 
 
 
 0.26 pM; C-Ag20
 
z8
 
, 11.25 
 
 
 
 2.88 pM)
Figure 2. C-Ag95z8 and C-Ag95z0 induce expression of c-fos in 
cultured cortical neurons. (A) 12-d-old cortical cultures were 
treated for 10 min with either C-Ag95z8 or C-Ag95z0, followed by 
double labeling with antibodies for Fos (fluorescein channel) and 
either MAP2 or GFAP (rhodamine channel). Cell bodies and nuclei 
of MAP2-positive neurons were intensely labeled for Fos in cultures 
treated with either C-Ag95z8 or C-Ag95z0. In contrast, only basal levels 
of Fos expression were observed in GFAP-positive nonneuronal 
cells. Induction of c-fos was agrin specific in that no detectable 
increase in Fos was apparent in cultures treated with prostate serum 
antigen control protein. Bar, 20  m. (B) Cultures were incubated for 
10 min in C-Ag95z8 (open circles, broken line) or C-Ag95z0 (filled 
circles, solid line), and levels of Fos expression were determined by 
in situ enzyme-linked assay as described in Materials and methods. 
Both agrin constructs induced essentially identical concentration-
dependent and saturable increases in c-fos expression. Data were 
normalized to maximal level of Fos expression in each experiment. 
Each point represents the mean of triplicate determinations from 
three independent experiments   SEM. Curves were fit by single-site 
nonlinear regression model R
2   0.94. Values from mock-treated 
sister wells have been subtracted.T
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were indistinguishable from each other and from those of the
C-Ag95
 
z0/8
 
 isoforms. In light of these observations, we con-
clude that the structural domains that mediate agrin induc-
tion of 
 
c-fos
 
 are contained within the C-Ag20
 
z0
 
 fragment.
 
Sequences flanking the z site are critical for 
agrin signaling
 
Agrin’s AChR clustering activity is regulated by alternative
splicing at the z site. However, the observation that a pep-
tide of the 8 amino acid alternatively spliced insert is itself
inactive (Gesemann et al., 1995) suggests that domains im-
portant for agrin’s bioactivity in muscle include not only the
z site, but also amino acids that flank it. Because inclusion of
alternatively spliced exons at the z site has no effect on agrin
activity in neurons, we sought to determine the role of se-
quences surrounding the z site. To address this question, we
deleted 37 amino acids from the NH
 
2
 
 terminus of C-Ag20
 
z0
 
to the border of the G3 domain, giving rise to a 15-kD
COOH-terminal fragment, C-Ag15 (Fig. 1).
Treatment with C-Ag15 alone had no effect on the levels
of Fos expression, even when present at a concentration five-
fold above saturation for C-Ag20
 
z0/8
 
 (unpublished data).
However, when added together with C-Ag95
 
z8
 
, C-Ag15 ap-
peared to inhibit the 
 
c-fos
 
–inducing activity of the larger
agrin fragment. To examine this effect in more detail,
C-Ag15 dose–response studies were performed in the pres-
ence of a near saturating (50 pM) concentration of C-Ag95
 
z8
 
.
Increasing concentrations of C-Ag15 inhibited the 
 
c-fos
 
–
inducing activity of C-Ag95
 
z8
 
 (Fig. 4 A). The curve was well
fit by a nonlinear regression model for single-site competi-
tion (R
 
2
 
 
 
 
 
 0.95) predicting an IC
 
50
 
 of 64.45 
 
 
 
 10.94 pM
and close to a 1:1 agonist:antagonist molar ratio. Similar re-
sults were also obtained for competition against 50 pM
C-Ag95
 
z0
 
 and the C-Ag20
 
z0/8
 
 isoforms (unpublished data).
To learn whether inhibition of agrin signaling by C-Ag15
might extend to other neurons or even muscle, mouse hip-
pocampal and cerebellar neurons or chick skeletal myotubes
were incubated with 50 pM C-Ag95
 
z8
 
 alone or in the pres-
ence of 1 nM C-Ag15, a concentration that blocks activity
in cortical neurons. Treatment with C-Ag95
 
z8
 
 triggered a ro-
bust increase in Fos levels in both populations of neurons
and in muscle compared with control sister cultures receiv-
ing vehicle (Fig. 4 B). However, co-incubation with C-Ag15
inhibited Fos expression in the neurons, but had no effect
Figure 3. The 20-kD COOH-terminal region of 
agrin is necessary and sufficient for induction of 
c-fos. (A) Cortical neurons were treated for 10 min 
with C-Ag 20 alone or in the presence of 50 pM 
C-Ag95z8 or C-Ag95z0. Neither a subsaturating 
(50 pM) nor supersaturating (50 nM) concentration 
of C-Ag 20 induced expression of c-fos, nor were 
they able to modulate the activity of the larger 
fragments. (B) In contrast, cortical cultures exhibited 
a concentration-dependent and saturable increase 
in response to C-Ag20z8 (open circles, broken line) 
or C-Ag20z0 (solid circles, solid line) similar to that 
seen with the C-Ag95z8/0 fragments. Data were 
normalized to the level of Fos expression induced 
by 50 pM C-Ag95z8 alone in A and maximal level of Fos expression in B. Each data point shows the mean of triplicate determinations from 
three independent experiments   SEM. Curves were fit by single-site nonlinear regression model R
2   0.97. Background levels of Fos expression 
from mock-treated sister cultures have been subtracted.
Figure 4. The 15-kD COOH-terminal region of agrin is a cell-
specific competitive inhibitor of C-Ag95z8 induction of c-fos. 
(A) Cortical cultures were incubated in 50 pM C-Ag95z8 in the presence 
of different concentrations of C-Ag15. C-Ag15 inhibited C-Ag95z8 
induction of c-fos in a concentration-dependent manner well 
described by a single-site competition model (R
2   0.95) with an 
IC50 of 64.5 pM; close to a 1:1 agonist:antagonist molar ratio. Data 
were normalized to percentage of Fos expression induced by 50 pM 
C-Ag95z8 alone, and represent the mean of triplicate determinations 
from three independent experiments   SEM. Background levels of 
Fos expression have been subtracted. (B) To test the cell specificity 
of C-Ag15 inhibition, hippocampal (Hip) or cerebellar (Cer) neurons 
and chick muscle fibers (Mus) were incubated in 50 pM C-Ag95z8 
alone (open bars) or in the presence (filled bars) of 1 nM C-Ag15. 
Levels of Fos expression were expressed as fold change over mock-
treated sister cultures such that a value of 1 indicates no change. 
C-Ag15 completely inhibited C-Ag95z8-induced expression of Fos in 
hippocampal and cerebellar neurons, but not in muscle. (C) The 
effect of C-Ag15 on C-Ag95z8-induced AChR aggregation was also 
tested. Cultured chick myotubes were incubated overnight in 50 pM 
C-Ag95z8 alone ( ) or in the presence ( ) of 1 nM C-Ag15, and 
AChR clusters were labeled with rhodamine-conjugated  -bungaro-
toxin. AChR clusters were counted blind with respect to treatment 
in five random fields/well and expressed as the ratio of clusters in 
mock-treated sister cultures. Consistent with the results of the Fos 
expression analysis, C-Ag15 had no effect on C-Ag95z8-induced 
AChR clustering. Bars in B and C represent the mean   SEM of 
triplicate wells from four independent experiments.T
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on muscle. Because agrin’s bioactivity in muscle is normally
measured in terms of its AChR clustering activity, we also
examined the ability of C-Ag15 to antagonize agrin-induced
clustering of AChR. Chick myotubes were incubated over-
night with 50 pM C-Ag95z8 alone or with 1 nM C-Ag15,
AChR labeled with rhodamine-conjugated  -bungarotoxin,
and the number of AChR clusters were determined. In line
with the results of the Fos assay, C-Ag15 had no effect on
the AChR clustering activity of C-Ag95z8 (Fig. 4 C). Based
on the results of these works, it appears that C-Ag15 is a spe-
cific antagonist for the neuronal receptor for agrin.
C-Ag20z0/8 rescues an agrin-deficient 
neuronal phenotype
Although induction of c-fos is a convenient reporter facilitat-
ing biochemical characterization of agrin signaling, its signif-
icance in terms of agrin function in CNS neurons is un-
known. Recently, we have provided evidence that agrin
plays an important role in neural differentiation by showing
that agrin-deficient neurons exhibit reduced responses to
glutamate both in cell culture and in vivo (Hilgenberg et al.,
2002). Therefore, to learn more about the role of the 20-kD
COOH-terminal region in agrin function, we tested the
ability of the C-Ag20 isoforms to rescue the agrin deficiency.
When grown in normal media, levels of glutamate-
induced Fos expression in agrin-deficient neurons were re-
duced by  70% compared with wild type. However, consis-
tent with our earlier findings, supplementing the growth
media for 2 d with a saturating concentration of either
C-Ag95z8 or C-Ag95z0 significantly increased the response of
agrin-deficient neurons close to wild-type levels (Fig. 5 A).
Similar results were obtained when agrin-deficient neurons
were grown in the presence of the C-Ag20z0/8 fragments.
Compared with agrin-deficient neurons in vehicle-sup-
plemented control media, treatment with either 5 nM
C-Ag20z8 or C-Ag20z0 resulted in a significant 2.2-fold in-
crease in glutamate response. Thus, not only do the
C-Ag20z0/8 isoforms exhibit full activity in terms of their
ability to induce c-fos, they are also competent to reverse the
physiological deficit resulting from loss of expression of full-
length agrin in the agrin-deficient cultures.
Despite its apparent effectiveness as an antagonist of
agrin-induced expression of c-fos, growth in media supple-
mented with up to 10 nM C-Ag15 had no effect on
glutamate-induced expression of c-fos in either wild-type or
heterozygous agrin-deficient neurons (unpublished data).
This suggests that C-Ag15 is unable to block signaling by
native agrin. However, the concentration of endogenous
agrin in our cultures is unknown, and may exceed the maxi-
mal concentration of C-Ag15 we were able to use, especially
if agrin is present as high density clusters on neuronal surface
membranes (see next section and Results). As an alternative
approach to examining the functional properties of the
C-Ag15 fragment, we tested its ability to inhibit rescue of
the agrin-deficient phenotype by C-Ag95z0/8. Inclusion of 10
nM C-Ag15 in the growth medium significantly reduced the
efficacy of 5 nM C-Ag95z0, blocking slightly more than half
(54%) of the rescue normally achieved by C-Ag95z0 alone
(Fig. 5 B). Similar results were also seen in single experi-
ments using either C-Ag95z8 or C-Ag20z8 (unpublished
data). Based on these observations we conclude that, under
the appropriate conditions, C-Ag15 can inhibit agrin func-
tion in CNS neurons.
Agrin receptors are concentrated at 
neuron–neuron synapses
The works described so far provide evidence for a neuron-
specific agrin receptor, and identify a minimal fragment of
agrin capable of activating it. Next, we sought to establish
the cellular distribution of the neuronal receptor for agrin
using the short agrin fragments as affinity ligands. Live corti-
cal cultures were incubated in C-Ag20z8, C-Ag20z0, or
C-Ag15, and were then labeled with an antibody against the
polyhistidine epitope tag to visualize bound agrin. A similar
pattern of labeling was evident for all three agrin fragments
and appeared as bright puncta scattered over neuronal so-
mata and neurites (Fig. 6). Labeling was specific in that non-
neuronal cells were not labeled (unpublished data), and little
or no labeling was evident when either the agrin fragments
were omitted or a  -galactosidase–myc–6His vector control
protein was used in their place (Fig. 6). More significantly,
binding of all three agrin fragments was completely blocked
in cultures labeled in the presence of a large excess of rC-Ag
with both “neural” rC-Agy4z8 and “inactive” rC-Agy0z0
appearing equally effective at blocking binding of either
C-Ag20z isoform or C-Ag15. Precise estimates of the con-
centration dependence of the competition between rC-Ag
and the short mouse agrin fragments are difficult to obtain
using immunofluorescence. However, NIH Image analysis
of the mean pixel intensities obtained from fixed exposure
photomicrographs of random fields revealed labeling to be
Figure 5. The 20-kD COOH-terminal region of agrin is the 
minimal fragment sufficient to rescue an agrin-deficient phenotype. 
(A) 10-d-old wild-type (filled bars) or agrin-deficient (open bars) 
cultures were grown for 2 d in media supplemented to 5 nM with 
the indicated agrin fragment. Cultures were challenged for 5 min 
with 100  M glutamate as described previously (Hilgenberg et al., 
2002), and the levels of Fos expression were determined. Data were 
normalized to levels of glutamate-induced Fos expression in mock-
treated wild-type cultures. Compared with mock, glutamate responses 
of homozygous agrin-deficient neurons were rescued to near wild-
type levels by either the long C-Ag95z8/0 or short C-Ag20z8/0 fragments 
(***, P   0.0005; **, P   0.002; *, P   0.02; paired t test). (B) To 
test the ability of C-Ag15 to antagonize agrin action, 10-d-old agrin-
deficient neurons were maintained for 2 d in the presence of 5 nM 
C-Ag95z0 alone or in combination with 10 nM C-Ag15, and neuronal 
responses to glutamate were determined as above. Treatment with 
C-Ag15 significantly (*, P   0.004; paired t test) inhibited rescue of 
the agrin-deficient response to glutamate by C-Ag95z0.T
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reduced by  30% in cultures coincubated with a 1:1 molar
ratio of C-Ag20z8 to rC-Agy4z8, and barely detectable at
1:100 (unpublished data). Together, these results provided
strong evidence that the bioactivity of the different agrin iso-
forms reported here is mediated through binding to a single
population of agrin receptors expressed on cortical neuron
cell membranes.
Previous papers have shown that agrin is present at neu-
ron–neuron synapses in peripheral ganglia and retina (Mann
and Kröger, 1996; Koulen et al., 1999; Gingras and Ferns,
2001). The punctate labeling observed with the short
COOH-terminal agrin fragments suggested that receptors
for agrin might also be synaptic. To test this hypothesis, we
first determined the distribution of endogenous agrin on
cultured cortical neurons by labeling live cultures with
R Ag-1, a pan-specific anti-agrin serum, followed by fixa-
tion and labeling with a second antibody against the synap-
tic vesicle protein synaptophysin. Agrin immunostaining
was distributed in patches on the neuronal cell bodies and
neurites, and colocalized with synaptophysin-positive nerve
terminals (Fig. 7). Although some variation in the intensity
of the immunostaining was evident, few (if any) agrin-posi-
tive/synaptophysin-negative or synaptophysin-positive/ag-
rin-negative patches were observed. Similar results were also
obtained using an anti-agrin mAb (MAB5204; CHEMI-
CON International, Inc.) and rabbit anti-synaptophysin an-
tiserum (unpublished data). Therefore, we conclude that
agrin is specifically localized at synapses formed between cul-
tured cortical neurons.
Next, to learn whether agrin receptors also exhibit a syn-
aptic pattern of expression, a parallel work was performed
in which live cortical cultures were labeled with C-Ag20z8,
C-Ag20z0, or C-Ag15 as before, followed by fixation and stain-
ing for synaptophysin. Irrespective of the agrin probe used, agrin
receptor clusters exhibited a high degree of colocalization with
the synaptic vesicle marker. Staining for synaptophysin was
specific; nonneuronal cells were not labeled by the synapto-
physin antibody (unpublished data), and nerve terminal stain-
Figure 6. Agrin receptor expression in nerve cell membranes. 
Live cortical neurons were incubated in C-Ag20z8, C-Ag20z0, or 
C-Ag15, either alone or in the presence of mock-conditioned 
medium or a 500-fold molar excess of the active (Rat C-Ag4,8) or 
inactive (Rat C-Ag0,0) isoform of rat agrin. Immunostaining with an 
anti-polyhistidine antibody reveals binding of the short agrin fragments 
to receptors distributed in numerous small clusters on neuron cell 
bodies and neurites; patches of agrin receptors outside the focal 
plane contribute to the diffuse staining evident in some neuron cell 
bodies. Consistent with a single class of agrin receptors, each fragment 
shows a similar pattern of binding that can be blocked by either 
isoform of rat agrin. The ability of rC-Ag to block the short agrin 
fragments is also strong evidence that binding is specific. In addition, 
no labeling was observed when the short agrin fragments were 
omitted or replaced by  -galactosidase ( -Gal) as a control for 
vector-specific sequences. Bar, 20  m.
Figure 7. Agrin and agrin receptors are colocalized at synaptic 
contacts. The subcellular distribution of endogenous agrin and 
agrin receptors on cultured cortical neurons was determined by 
labeling with either an anti-agrin serum, R Ag-1, or short agrin 
fragment, followed by fixation and incubation with an antibody 
to synaptophysin to identify nerve terminals by labeling synaptic 
vesicles. Both agrin and the agrin receptor were present at virtually 
all synaptophysin-positive nerve terminals (arrowheads), evidence 
that agrin and its receptor are colocalized at synaptic sites. Nerve 
terminal staining was specific, and was not observed in control 
cultures labeled with an agrin receptor probe in the absence of the 
anti-synaptophysin antibody. Bar, 20  m.T
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ing was not observed in cultures treated with C-Ag20z0 or
other short fragments in the absence of the anti-synapto-
physin antibody (Fig. 7). Together with the agrin immuno-
staining, the results of these studies show that both agrin and
its receptor are concentrated at neuron–neuron synapses.
Discussion
Several papers have provided evidence that agrin plays a role
in differentiation of CNS neurons. In particular, using the
immediate early gene c-fos as a reporter, we have character-
ized an agrin-signaling pathway that influences development
of neuronal responses to excitatory neurotransmitters and
depolarization (Hilgenberg et al., 1999, 2002). To learn
more about the receptor mediating agrin’s function in brain,
we have analyzed the structural features of agrin required for
activation of its signaling pathway. Our results confirm
agrin’s activity in CNS neurons is independent of alternative
splicing at the z site, and demonstrate further that agrin’s
functional domains reside within 20 kD of its COOH ter-
minus. Also, we show that the receptor mediating these
agrin-dependent signals is colocalized with agrin at neuron–
neuron synapses. Here, we discuss the implications of our
findings for agrin function and the identity of its receptor in
CNS neurons.
Initial attempts to characterize molecules that might me-
diate agrin-induced clustering of AChR identified  -dystro-
glycan as a major agrin-binding protein in muscle cell mem-
branes (Campanelli et al., 1994; Gee et al., 1994). Although
it now seems unlikely to represent the “functional” agrin re-
ceptor, evidence suggests that  -dystroglycan still plays an
important role in consolidation and maintenance of AChR
clusters once formed (Jacobson et al., 1998, 2001; Heath-
cote et al., 2000). Dystroglycan is also found in mammalian
brain, where its expression and synaptic localization have
suggested a role in synaptic function (Tian et al., 1996; Zac-
caria et al., 2001; Lévi et al., 2002). Interestingly, several
biochemical properties of agrin induction of c-fos in CNS
neurons, including Ca
2  dependence, inhibition by heparin,
and ability to bind z
  and z
  isoforms (Hilgenberg et al.,
1999), are consistent with agrin binding to  -dystroglycan
(Sugiyama et al., 1994; Gesemann et al., 1996). High af-
finity binding of agrin to  -dystroglycan is mediated by
a region that includes the first two laminin G domains
(Gesemann et al., 1996; Hopf and Hoch, 1996). However,
C-Ag 20, which contains the G1 and G2 domains, neither
induced c-fos nor inhibited the activity of the larger frag-
ments. Conversely, both C-Ag20z0/8 isoforms, lacking do-
mains for high affinity binding to  -dystroglycan, induced
c-fos and rescued the agrin-deficient phenotype with a simi-
lar efficacy as their 95-kD C-Agz0/8 counterparts. Although
these results do not rule out a role for  -dystroglycan medi-
ating other aspects of agrin signaling,  -dystroglycan is un-
likely to be a component of the agrin receptor mediating the
responses measured here.
Also, we considered the possibility that the MuSK–MASC
complex might mediate agrin signaling in neurons. Both
neural and muscle signaling pathways are activated by pico-
molar concentrations of agrin, are inhibited by heparin, and
are Ca
2  dependent (Hilgenberg et al., 1999). Even more
striking is the fact that the same minimal agrin fragment is
sufficient to activate the MuSK–MASC complex (Gese-
mann et al., 1995) and neuronal receptor; evidence that sig-
nificant structural homology exists between the two recep-
tors. However, despite these similarities, we believe the
neuronal and muscle receptors are distinct. MuSK expres-
sion has not been detected in either embryonic or adult
mammalian brain (Valenzuela et al., 1995). Moreover, al-
though a critical determinant of agrin’s AChR clustering ac-
tivity in muscle (Ferns et al., 1992; Ruegg et al., 1992; Gese-
mann et al., 1995), alternative splicing at the z site has no
effect on agrin’s bioactivity assayed here, even in the case of
the smallest active fragment where variations in structure
might be expected to exert the greatest effect. The finding
that the C-Ag20z0/8 fragments are fully active also contrasts
with observations in muscle where the AChR clustering ac-
tivity of the corresponding fragment is  100-fold lower
than the 95-kD C-Ag polypeptide from which it was derived
(Gesemann et al., 1995). Together with the inability of
C-Ag15 to antagonize agrin induction of either c-fos or
AChR clustering in muscle, these data point to a fundamen-
tal difference in the receptors that catalyze the agrin response
in nerve and muscle cells.
The inhibition of c-fos induction by C-Ag15, its ability to
block rescue of the agrin-deficient phenotype, distribution
of binding sites, and ability of different agrin isoforms to
block binding to them argue that C-Ag15 and the active
agrin polypeptide fragments compete for a common binding
site on the neuronal receptor for agrin. How then might
C-Ag15 bind to the receptor but not activate it? One possi-
bility is that deletion of the 5-kD NH2-terminal region may
have disordered secondary or tertiary structures in the re-
maining G3 and COOH-terminal domain necessary for sig-
naling. However, that such a structural change could occur
without affecting the apparent affinity of C-Ag15 binding to
the receptor seems improbable. Alternatively, activation of
the receptor may require agrin binding to two sites, with the
5-kD NH2-terminal region of C-Ag20z0/8 targeted to the
second site. The agrin receptor in muscle is made up of two
components (MuSK and MASC) although agrin appears
only to bind directly to MASC (Glass et al., 1996). Whereas
a similar two-component model of the neuronal receptor for
agrin would be consistent with our data, the fact that
C-Ag15 has no effect on agrin’s bioactivity in muscle sug-
gests that, although functionally homologous to MASC, the
agrin-binding component of the neuronal receptor would be
structurally distinct.
Blocking agrin expression with antisense oligonucleotides
inhibits synapse formation and alters synaptic function in
CNS neurons (Ferreira, 1999; Böse et al., 2000). The ability
of rC-Ag95z8 (but not rC-Ag95z0) to rescue changes induced
by the antisense oligonucleotides suggests these effects are
mediated by a loss of isoform-specific signals associated with
agrin’s COOH-terminal domains (Ji et al., 1998; Böse et al.,
2000). These observations contrast to our own findings that,
in terms of their ability to induce c-fos and rescue an agrin
mutant phenotype, the bioactivity of even the shortest alter-
natively spliced active fragments are the same. One possible
explanation for this apparent inconsistency is that different
domains within the 95-kD COOH-terminal region of agrinT
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might mediate distinct responses through specific receptors.
In this regard, it is interesting to note that a recent paper
showed that in addition to  -dystroglycan/heparin binding,
the 95-kD COOH-terminal region of agrin contains three
other sites that interact with neuronal cell surface receptors
(Burgess et al., 2002). Two of these sites are targeted to inte-
grins, one of which modulates agrin’s AChR clustering ac-
tivity, whereas the receptor for the third site, located within
20 kD of agrin’s COOH terminus, has yet to be identified.
It will be interesting, in light of these observations, to deter-
mine whether C-Ag15 inhibition is limited to the bioassays
used here, or whether it extends to other agrin-dependent
neuronal responses.
Agrin induces expression of c-fos in CNS neurons, and
mutation of the agrin gene decreases neuronal responses to
excitatory neurotransmitters (Hilgenberg et al., 2002). Al-
though neurons express multiple molecules capable of bind-
ing agrin, several lines of evidence support the conclusion
that the agrin-binding sites visualized using the affinity
probes are the receptors responsible for the physiologic re-
sponses to agrin reported here and earlier (Hilgenberg et al.,
1999). First, the apparent affinities and potency of the vari-
ous agrin fragments, in terms of their c-fos–inducing activity
or ability to rescue the agrin-deficient phenotype, are the
same. Moreover, the ability of the smallest agrin fragment,
C-Ag15, to inhibit both c-fos induction and rescue of the
agrin-deficient phenotype is strong evidence for a common
receptor mediating both activities. A similar profile was also
apparent for the binding properties of the agrin fragments
when used to visualize the distribution of the agrin receptors.
Consistent with the biochemical studies, neurons were
clearly labeled using agrin concentrations in the picomolar
range irrespective of z site composition. Most importantly,
the distribution of high density binding sites for C-Ag15 and
their sensitivity to blockade by rC-Agz0/8 was indistinguish-
able from that observed with either C-Ag20z0/8 constructs.
Previous papers have shown that agrin is concentrated at
cholinergic synapses formed between cultured sympathetic
neurons (Gingras and Ferns, 2001) and GABAergic syn-
apses in the retina (Mann and Kröger, 1996; Koulen et al.,
1999). Cultured cortical neurons receive both glutamater-
gic and GABAergic inputs (Li et al., 1997), and because no
evidence of synaptic contacts lacking agrin was found, we
can extend these findings to include glutamatergic synapses
as well. A similarly high correlation between agrin receptors
and nerve terminals was also evident, suggesting that agrin
and its receptor colocalize at synaptic sites. Together, these
observations suggest that regardless of neurotransmitter
phenotype, synapses are likely to be significant sites of agrin
action. Consistent with these conclusions, agrin has been
implicated in regulating a number of pre- and postsynaptic
properties of cholinergic, glutamatergic, and GABAergic
neurons (Ferreira, 1999; Böse et al., 2000; Gingras et al.,
2002). Higher resolution techniques than those used here
will be required to determine the agrin receptor’s subcellu-
lar distribution. However, if all agrin receptors are presyn-
aptic, then a long-range retrograde signal would be needed
to account for agrin’s ability to rapidly induce c-fos. There-
fore, it seems likely that at least some agrin receptors, for ex-
ample, those at or near the neuronal soma, are postsynaptic.
At the neuromuscular junction, agrin is anchored to the
synaptic basal lamina by a laminin-binding domain present
within its NH2 terminus (Denzer et al., 1995). However,
the mechanism controlling agrin’s spatial organization in
neurons, and in particular, its concentration at synaptic
sites, is unknown. Neuron–neuron synapses lack a basal
lamina; moreover, the short NH2-terminal form of agrin
(SN-agrin) expressed in CNS neurons not only lacks the
laminin-binding domain, but consistent with a type II
membrane protein, is oriented such that its NH2 terminus is
cytoplasmic (Burgess et al., 2000; Neumann et al., 2001).
That signals embedded within this cytoplasmic domain
might play a role in agrin’s subcellular localization also
seems unlikely. Fusion of the SN-agrin NH2 terminus to
YFP directs YFP to neuronal membranes, but the pattern of
expression is uniform rather than concentrated at synaptic
sites (Burgess et al., 2002). In light of these findings, agrin’s
spatial distribution would seem to be defined by interactions
between its extracellular domains and candidate neuronal
cell surface agrin-binding proteins such as neural cell adhe-
sion molecules, integrins, and  -dystroglycan. Clearly, the
high affinity and synapse-specific pattern of expression of
the neuronal receptor for agrin are also consistent with the
possibility that, in addition to signal transduction, it could
play a role sculpting agrin’s spatial distribution. Future stud-
ies comparing the time course of agrin and agrin receptor ex-
pression and any effect C-Ag15 might have on agrin’s distri-
bution will be helpful in testing this hypothesis.
Materials and methods
Tissue culture
Mouse cortical cultures were prepared from newborn or 1-d-old ICR strain
mice (Harlan) as described previously (Hilgenberg et al., 1999). For the
first 24 h after plating, cells were maintained in neural basal medium
(NBM) plus B27 supplements (Invitrogen), and in nonneuronal cell–condi-
tioned NBM (cNBM) plus B27 thereafter, at 37 C in humidified 5% CO2 at-
mosphere. To further reduce proliferation of nonneuronal cells, cultures on
glass coverslips used for histology were treated with 5  M 5-fluoro-2-
deoxyuridine (Sigma-Aldrich) 3–4 d after plating. Hippocampal and cere-
bellar cultures were prepared in a similar manner. Experiments were per-
formed on 10–14-d-old cultures.
Agrin-deficient neuron cultures were prepared from cortices of embry-
onic d 18–19 fetuses resulting from matings between mice heterozygous
for a mutation in the agrin gene (Gautam et al., 1996). Cultures were pre-
pared and genotyped as described previously (Li et al., 1999), and were
maintained as above.
Chick muscle cultures were prepared from pectoral muscles of 10–11-
d-old White Leghorn chick embryos as described previously (Hilgenberg et
al., 1999). Experiments were performed on 4–6-d-old cultures.
Expression constructs
Parent constructs, C-Ag95z0 and C-Ag95z8 (Fig. 1), encoding the soluble
95-kD COOH terminus of mouse agrin, were generated from cDNA pre-
pared by RT-PCR of adult mouse cortex RNA using the F95/R95 primer
pair (Table I) subcloned into the pGEM-T (Promega) shuttle vector and
transformed into JM109-competent bacteria. Individual ampicillin-resistant
colonies were picked, and C-Ag95z0- and C-Ag95z8-containing clones
were identified by PCR analysis using primers F24/B2 flanking the z site.
After double digestion of the BamHI and EcoRV l linker sites contained
within the F95 and R95 primers, agrin inserts were gel purified and ligated
into the pSecTag2B expression vector (Invitrogen) in frame with a COOH-
terminal myc epitope and 6  polyhistidine tag.
C-Ag 20 lacking the 20-kD COOH-terminal region of C-Agz0/8 was pre-
pared by PCR amplification of the C-Ag95z8 pGEM-T template using F95
and the reverse primer R 20 that includes a 3  EcoRV site. DNA from the
PCR reaction was digested with BamHI and EcoRV, gel purified, and li-
gated into pSecTag2B.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 Agrin receptor at central synapses | Hoover et al. 931
A similar strategy was used to generate C-Ag20z0/8 and C-Ag15 constructs
by PCR amplification of the appropriate pGEM-T C-Agz0/8 template using ei-
ther F20 (for C-Ag20z0/8) or F15 (for C-Ag15) in combination with R20.
However, for more efficient expression, aliquots of the PCR reaction were li-
gated into the inducible bacterial expression vector pTrcHis2 (Invitrogen).
Expression and quantitation of recombinant agrin
pSecTag2B agrin vector DNA encoding either C-Agz0/8 or C-Ag 20 was
transfected into HEK 293T cells using LipofectAMINE™ (Invitrogen) ac-
cording to the manufacturer’s directions. Controls were either sham trans-
fected with LipofectAMINE™ alone or with control vector encoding pros-
tate-specific antigen (pSecTag2-PSA). Agrin constructs in the pTrcHis2
expression vector were maintained in the JM109 bacteria. The plasmid
pTrcHis2-lacZ encoding  -galactosidase was expressed as a control.
Polyhistidine-tagged agrin fragments were purified from conditioned
media and bacterial extracts using the Talon™ (CLONTECH Laboratories,
Inc.) metal affinity resin eluted with 200–500 mM imidazole (Sigma-
Aldrich) according to the manufacturer’s instructions. The identity of the
isolated fragments was confirmed by immunoblot analysis using R Ag-1, a
rabbit antiserum raised against a synthetic peptide corresponding to amino
acids 1862–1895 conserved in all isoforms of mouse agrin. For some ex-
periments, the elution buffer was removed by dialysis against PBS or 20
mM Tris and 250 mM NaCl, pH 8.0.
The molar concentration of each fragment was determined by compari-
son to a C-Ag95z0 standard prepared as follows: HEK 293T cells were
transfected with pSecTag2B-C-Agz0, and were then transferred to 80% me-
thionine-free DME containing 100  Ci/ml [
35S]methionine. C-Ag95z0
present in the medium was purified over a Talon™ metal affinity resin col-
umn, and the apparent molar concentration was determined by counting
aliquots of the column eluate in a scintillation counter (model LS7500;
Beckman Coulter). A small correction factor was applied to account for the
fraction of counts incorporated into C-Ag95z0 ( 90%) versus total counts
determined by phosphorimager analysis (Molecular Dynamics, Inc.) of an
aliquot of the eluate separated on an 8% SDS-PAGE gel.
The concentration of the other agrin fragments was determined by
comparison to a 
35S-labeled C-Ag95z0 standard in immunoblots probed
with a mouse anti-myc antibody (Invitrogen) and 
125I-labeled anti–mouse
second antibody (Amersham Biosciences). The amount of 
125I bound to
both the standard and unknown was determined by phosphorimager anal-
ysis and, after correcting for the contribution of the [
35S]methionine in the
standard, the concentration of the unknown was determined from the
standard curve.
Soluble 95-kD COOH-terminal fragments of rat agrin (rC-Agy4z8/y0z0)
were harvested in media conditioned by transiently transfected COS-7
cells (Hilgenberg et al., 1999) and dialyzed against PBS. The concentration
of the rC-Ag was estimated by comparison to a mouse agrin standard in the
c-fos induction assay and by immunoblot analysis with R Ag-1.
Quantitative analysis of Fos expression
Fos expression in cortical cultures was measured by in situ enzyme-linked
immunoassay (Hilgenberg et al., 1999). In brief, 11–14-d-old neuronal cul-
tures were treated for 10 min with agrin or other agent diluted in NBM or
PBS, then washed in cNBM and returned to the incubator for 2 h. Cultures
were rinsed in PBS, fixed in ice cold 4% PFA, and blocked in PBS contain-
ing 0.1% Triton X-100 and 4% BSA (PBSTB) before being incubated in a
primary rabbit antibody against Fos (Ab-2; Oncogene Research Products)
and secondary goat antibody against mouse conjugated to alkaline phos-
phatase (Southern Biotechnology Associates, Inc.). The level of Fos expres-
sion was determined by monitoring conversion of p-nitrophenyl phosphate
to a soluble yellow reaction product at 405 nm.
AChR clustering assay
4–6-d-old myotubes were treated with agrin overnight followed by in-
cubation with 20 nM rhodamine-conjugated  -bungarotoxin (Molecular
Probes, Inc.) in culture medium for 1 h at 37 C. Cells were then fixed in
4% PFA in PBS, washed in PBS, and viewed at 200  under epifluorescent
illumination on a microscope (Optiphot-2; Nikon). For each well, the
mean number of AChR clusters/field was determined from counts obtained
from five random fields. All counts were performed blind with respect to
treatment. To facilitate comparison between experiments, the number of
AChR clusters/field was normalized to the cluster density of control cul-
tures treated with vehicle alone.
Fos immunohistochemistry
10–14-d-old cortical neurons, grown on glass coverslips, were treated with
agrin, fixed, and blocked as for the Fos in situ enzyme-linked immunoas-
say. Cells were double labeled overnight at 4 C with Ab-2 (1:200) together
with either a mouse monoclonal antibody against MAP2 (SMI-52; 1:400;
Sternberger Monoclonals), or GFAP (G-A-5; 1:1,000; Sigma-Aldrich) in
PBSTB to identify neurons or glial cells, respectively. Bound antibodies
were visualized by incubation for 2 h at RT in a mixture of fluorescein-con-
jugated goat anti–rabbit and Texas red–labeled goat anti–mouse secondary
antibodies (Vector Laboratories) diluted 1:200 in PBSTB. Coverslips were
washed in PBS, mounted in Fluoromount™ (Southern Biotechnology Asso-
ciates, Inc.), and examined using epifluorescent illumination.
Agrin immunohistochemistry
Live cortical cultures on glass coverslips were incubated for 30 min at
37 C in R Ag-1 diluted 1:500 in NBM. Cultures were then washed in
NBM, fixed and blocked as described for the Fos in situ enzyme-linked im-
munoassay, and were then washed and incubated overnight at 4 C with
the anti-synaptophysin antibody, SVP38 (Sigma-Aldrich), diluted 1:400 in
PBS containing 4% BSA (PBSB). Primary antibodies were visualized by
double labeling with fluorescein-conjugated goat anti–rabbit and Texas
red–labeled anti–mouse antibodies as above.
Agrin receptor immunohistochemistry
The distribution of agrin receptors was studied using agrin deletion frag-
ments as affinity probes. Neurons, plated on glass coverslips, were washed
briefly (1–2 min) in cold PBS containing 10 mM EDTA followed by a sec-
ond wash in cold PBS alone before incubation for 15 min at 4 C with 1 pM
recombinant mouse agrin in NBM. In some experiments, labeling with
mouse agrin was performed in the presence of various concentrations of
rat rC-Ag95y4z8 or rC-Agy0z0. Control cultures were treated with vector con-
trol protein or an equivalent volume of vehicle in which the recombinant
agrin was dissolved. Cells were then washed in cold NBM, fixed for 40
min on ice in 4% PFA in PBS, then washed in PBS and blocked for 1 h in
PBSB. Recombinant agrin was detected through the COOH-terminal 6 
polyhistidine tag using an anti-his antibody (1:500; Invitrogen). In experi-
ments where cells were double labeled for synaptophysin, the anti-synap-
tophysin antiserum (1:400) was also added at this step. Incubations were
performed overnight at 4 C in PBSB, followed by labeling with fluorescein-
conjugated goat anti–mouse and Texas red–labeled anti–rabbit antibodies
as described in the previous paragraphs. In some experiments, the amount
of mouse agrin bound was estimated by digital photomicrography using
the public domain NIH Image program (http://rsb.info.nih.gov/nih-image/).
The authors thank Betty Sicaeros for technical assistance and Dr. Diane
O’Dowd for critical reading of the manuscript.
This work was supported by National Institutes of Health grant
NS33213 to M.A. Smith.
Table I. PCR primers
Construct Primer Sequence Nucleotide
C-Agy4z0/8 F95 TAGGATCCACCGCCAGTATTGACCGA 1104–1121
R95 TAGATATCAGAGTGGGGCAGGGTCTT 6678–6663
C-Ag ∆20 R∆20 TAGATATCGTCCGCCCATCAAAGGCC 4585–4568
C-Ag20z0/8 F20 AATGGATCCTCGGACCTACATCG 4581–4593
R20 TTCGAATTCAGAGTGGGGCAGGG 6679–6666
C-Ag15 F15 AATGGATCCGTGGATTGGCAAGGC 5750–5764
Engineered BamHI and EcoRV restrictions sites, in forward and reversed primers, respectively, are underlined. Nucleotide positions are numbered according
to Rupp et al. (1992).T
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